Oyster point market cap
WebAs of April 2024 Oyster Point Pharma has a market cap of $0.29 Billion. This makes Oyster Point Pharma the world's 5790th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of … WebOyster Point Market Capitalization is currently at 207.74 M. Market Capitalization is the total market value of Oyster Point's equity. It is one of many ways to value Oyster Point and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price …
Oyster point market cap
Did you know?
WebMarket cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares … Web2 days ago · These wine cap mushrooms can be grown from sawdust spawn sold by North Spore. (Courtesy of North Spore) In the first few days after you open the package, mycelium creates a dense spiderweb beneath ...
WebWhat is OYST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors. Price-To-Sales vs Fair Ratio: OYST is expensive based on its Price-To-Sales Ratio (15.5x) compared to the estimated Fair Price-To-Sales Ratio (8.3x). WebMarket Cap US$303.2m 7D 0% 1Y -29.7% Updated 04 Jan, 2024 Data Company Financials + 3 Analysts Oyster Point Pharma, Inc. NasdaqGS:OYST Stock Report Mkt Cap: US$303.2m Add to watchlist CompanyOverview 1Valuation 2Future Growth 3Past Performance 4Financial Health 5Dividend 6Management 7Ownership OtherInformation OYSTStock …
WebAug 25, 2024 · Select News Releases. Jan 03, 2024. Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division. Sep 27, … WebOct 27, 2024 · Our most recent data indicates that insiders own some shares in Oyster Point Pharma, Inc.. It has a market capitalization of just US$288m, and insiders have US$3.7m …
WebOyster Point Pharma Inc OYST stock $11.17 0.18% $300 M 0.00% $0.00 - Ratings - OYST Dividend Safety ? Years of consecutive dividend increase. Yield Attractiveness ? Forward dividend yield Returns Risk ? Beta. Returns Potential ? Price target upside according to sell-side analysts. Quant Recommendation - OYST
WebJan 3, 2024 · PITTSBURGH, Jan. 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed its acquisitions of Oyster … receptor drawingWebAug 11, 2024 · With a market capitalization of US$670m, Oyster Point Pharma is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the... receptor de bluetooth para pcWebOff Market. $637,100. 2 bd 3 ba -- sqft. 23300 SE Black Nugget Rd UNIT C5, Issaquah, WA 98029. Off Market. Skip to the beginning of the carousel. Neighborhood stats provided by … receptor editing and toleranceWebYou can watch Oyster Point Pharma (OYST) and buy and sell other stocks, ETFs and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. ... Market cap. 299.71M. Market cap 299.71M. Price-Earnings ratio-1.68. receptor editing of b cellWebCurrent and historical revenue charts for Oyster Point Pharma. As of March 2024 Oyster Point Pharma's TTM revenue is of $19.58 M companies: 7,318 total market cap: $86.516 T unlawful temptation bookWebJun 1, 2024 · Is Oyster Point Pharma, Inc. (OYST) A Good Stock To Buy? Abigail Fisher June 1, 2024, 8:39 AM · 6 min read At the end of February we announced the arrival of the first US recession since 2009 and... receptor elsysWebLatest Market Cap: $313,475,891. ... Novavax, Spectrum stocks, a deal for Oyster Point, Ji.....commercialization rights outside of Korea, China and Japan, where Hanmi Pharmaceutical Co. Ltd. (KSE:128940) holds rights. Oyster Point.....Xing gains exclusive rights to develop and commercialize varenicline (OC-01) and simpinicline (OC-02). receptor editing in t cells